Published in Mental Health Business Week, July 23rd, 2005
The final results of the study will be presented at the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
BENEFIT, a multicenter, randomized, double-blind, placebo-controlled phase 3 study was designed to investigate the efficacy and safety of interferon beta-1b (Betaferon/Betaseron) in patients with first clinical symptoms indicative of multiple sclerosis (MS).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week